FX Dialyzers
FX CorAL dialyzers: a new frontier in HighVolumeHDF
With its cutting-edge Helixone hydro membrane and nature-inspired engineering*, the FX CorAL has many benefits including1,11:
- A smooth surface for uninterrupted treatment
- Hydro-layer on inner surface that reduces protein absorption and enhances hemocompatibility
- Lowered blood cell injury and platelet loss
- Efficient clearance of middle to large toxins
*Nature-inspired engineering: the hydro-layer was inspired by the natural phenomenon of water’s ability to roll off surfaces.
Enhancing dialysis care
Watch to learn more about the innovative Helixone hydro membrane.
Backed by evidence and clinical studies.
FX CorAL enables hemodiafiltration, which reduces all-cause and cardiovascular mortality in incident hemodialysis patients.
Efficient reduction ratios
FX CorAL dialyzers show efficient reduction ratios of large medium-sized molecules in post-dilution HDF. Studies have proven reduction ratio of the following13:
- 86.72% for ß2-microglobulin (11,8 kDa)
- 71.59% for myoglobin (17,2 kDa)
- 71.51% for kappa-free Ig light chains (22,5 kDa)
- 42.49% for lambda-free Ig light chains (45 kDa)
- 73.04% for prolactin (23 kDa)
- 25.33% for α1-microglobulin (33 kDa)
- 13.27% for α1-acid glycoprotein (41 kDa)
Discover additional dialyzers from our portfolio
FX dialyzers: performance overview
Model | Flux | Sieving coefficient (B2M) | Surface areas | Sterilization method | Key benefit |
FX CorAL | High | 1.0 | 9 | INLINE steam | Preferred choice for hemodiafiltration and high-volume hemodiafiltration, offering a well-rounded profile with excellent performance and biocompatibility. Its ability to help reduce inflammation linked to progression of CVD makes it suitable for the high-volume HDF therapy.10,19,21 |
FX CorDiax | High | 0.9 | 9 | INLINE steam | Designed for high-efficiency, high-flux dialysis to enhance the removal of middle-molecular uremic toxins, including ß2-microglobulin and myoglobin |
FX classix | High | 0.7 | 4 | INLINE steam | Engineered for patients transitioning from low-flux to high-flux dialysis, ensuring smooth transition. |
FX class | Low | 0.8 | 5 | INLINE steam | Therapeutically suitable for new dialysis patients requiring a slow and gentle therapy, with a focus on small molecule (urea) removal and optimized ultrafiltration for effective fluid management. |
FX paed | Low |
| 1 | INLINE steam | For pediatric patients with small patient size and body weight. |
Your questions answered
High-flux dialyzers have a larger pore size and higher ultrafiltration coefficient (Kuf), allowing enhanced removal of middle-molecular-weight solutes such as β2-microglobulin. Low-flux dialyzers have smaller membrane pores and lower Kuf, primarily clearing small solutes like urea and creatinine.
FX dialyzer Helixone membranes enhance biocompatibility by modifying surface properties, such as increasing hydrophilicity to reduce blood cell activation, inflammation, and thrombosis.
Endotoxin retention is crucial in hemodialysis to prevent the passage of harmful pyrogenic substances from dialysis fluid into the patient's bloodstream.
The Helixone plus membrane has demonstrated high efficacy in removing middle molecules such as β2-microglobulin, suggesting its potential benefit in managing β2-microglobulin amyloidosis in dialysis patients.
The FX paed dialyzer is specifically designed for newborns and children weighing up to 10 kg, supporting optimal blood flow rates between 30 and 100 mL/min.
The FX dialyzer range features polypropylene housing, reducing waste by up to 1,200 kg and lowering CO₂ emissions compared to polycarbonate dialyzers, resulting in a lower environmental footprint.22
1 Maduell F, Broseta JJ, Rodríguez-Espinosa D, et al. Comparison of efficacy and safety of the new generation helixone dialyzers. Nefrologia (Engl Ed). 2024;44(3):354-361.
2 Liabeuf S, Lenglet A, Desjardins L, et al. Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. Kidney Int. 2012;82:1297-1303.
3 Ahrenholz PG, et al. Clinical nephrology. Clin Nephrol. 2004;62(1):21-28.
4 Allard B, Begri R, Potier J, et al. Dialyzers’ biocompatibility and efficiency: determinants of sterilization method choice. Pharm Hosp Clin. 2013;48:e15-e21.
5 Schindler R, Christ-Kohlrausch F, Frei U, Shaldon S. Differences in the permeability of high-flux dialyzer membranes for bacterial pyrogens. Clin Nephrol. 2003;59(6):447-454.
6 Weber V, Linsberger I, Rossmanith E, et al. Pyrogen transfer across high- and low-flux hemodialysis membranes. Artif Organs. 2004;28(2):210-217.
7 Hornig C, Bowry SK, Kircelli F, et al. Hemocompatibility in hemodialysis-related therapies and their health economic properties. J Clin Med. 2024;13(20):6165.
8 Żebrowski P, Zawierucha J, Prystacki T, Marcinkowski W, Małyszko J. Medical waste management—how industry can help protect the environment and save money. Ren Fail. 2020;42(1):547-549.
9 Blankestijn PJ, Vernooij RWM, Hockham C, et al. Effect of hemodiafiltration or hemodialysis on mortality in kidney failure. N Engl J Med. 2023;389:700-709.
10 Ehlerding G, Ries W, Kempkes-Koch M, et al. Randomized comparison of three high-flux dialyzers during high-volume online hemodiafiltration—the comPERFORM study. Clin Kidney J. 2022;15:672-680.
11 Zawada AM, Griesshaber B, Ottillinger B, et al. Development and investigation of a new polysulfone dialyzer with increased membrane hydrophilicity. Membranes (Basel). 2025;15(5):132.
12 Maduell F, Moreso F, Pons M, et al; ESHOL Study Group. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol. 2013;24(3):487-497.
13 Maduell F, Escudero-Saiz VJ, Cuadrado-Payán E, et al. A study on the safety and efficacy of an innovative hydrophilic dialysis membrane. Membranes (Basel). 2025;15(1):30.
14 Locatelli F, Canaud B, Eckardt KU, et al. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant. 2003;18:1272-1280.
15 Wanner C, Bahner U, Mattern R, et al. Effect of dialysis flux and membrane material on dyslipidemia and inflammation in hemodialysis patients. Nephrol Dial Transplant. 2004;19:2570-2575.
16 Merello Godino JI, Rentero R, Orlandini G, et al. Results from EuCliD (European Clinical Dialysis Database): impact of shifting treatment modality. Int J Artif Organs. 2002;25:1049-1060.
17 Potier J, Bowry S, Canaud B. Clinical performance assessment of CorDiax filters in hemodialysis and hemodiafiltration. Contrib Nephrol. 2017;189:237-245. doi:10.1159/000450810.
18 Maduell F, Broseta JJ, Rodríguez-Espinosa D, et al. Comparison of four medium cut-off dialyzers. Clin Kidney J. 2022;15(12):2292-2299.
19 Haq Z, Wang X, Cheng Q, et al. Bisphenol A and bisphenol S in hemodialyzers. Toxins (Basel). 2023;15
20 Melchior P, Erlenkötter A, Zawada AM, et al. Complement activation by dialysis membranes and its association with secondary membrane formation and surface charge. Artif Organs. 2021;45:770-778.
21 Ehlerding G, Erlenkötter A, Gauly A, et al. Performance and hemocompatibility of a novel polysulfone dialyzer: a randomized controlled trial. Kidney360. 2021;2:937-947.
22 Fresenius Medical Care Deutschland GmbH. Internal study: comparative life cycle assessment of selected FME dialysers. Unpublished data. 2018.